Is the Fixed Periodic Treatment Effective for the Tumor System without Complete Information?
Jiali Wang,1,2 Yixuan Zhang,1,2 Xiaoquan Liu,1,2 Haochen Liu1,2 1School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, People’s Republic of China; 2Center of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, 210009, People’s Republic of ChinaCorresponden...
Guardado en:
Autores principales: | Wang J, Zhang Y, Liu X, Liu H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8d0e87111a09445f9834725a0e68eb9c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation
por: Jiali Wang, et al.
Publicado: (2021) -
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021) -
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner SJ, et al.
Publicado: (2017) -
Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021) -
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)